Mediterranean Journal of Hematology and Infectious Diseases (May 2011)

GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS

  • Angela Stoddart,
  • Megan E. McNerney,
  • Elizabeth Bartom,
  • Rachel Bergerson,
  • David J. Young,
  • Zhijian Qian,
  • Jianghong Wang,
  • Anthony A. Fernald,
  • Elizabeth M. Davis,
  • Richard A. Larson,
  • Kevin P. White,
  • Michelle M. Le Beau

DOI
https://doi.org/10.4084/mjhid.2011.019
Journal volume & issue
Vol. 3, no. 1
pp. e2011019 – e2011019

Abstract

Read online

Therapy-related myeloid neoplasm (t-MN) is a distinctive clinical syndrome occurring after exposure to chemotherapy or radiotherapy. t-MN arises in most cases from a multipotential hematopoietic stem cell or, less commonly, in a lineage committed progenitor cell. The prognosis for patients with t-MN is poor, as current forms of therapy are largely ineffective. Cytogenetic analysis, molecular analysis and gene expression profiling analysis of t-MN has revealed that there are distinct subtypes of the disease; however, our understanding of the genetic basis of t-MN is incomplete. Elucidating the genetic pathways and molecular networks that are perturbed in t-MNs, may facilitate the identification of therapeutic targets that can be exploited for the development of urgently-needed targeted therapies.

Keywords